Navigation Links
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Date:8/19/2007

NEW HAVEN, Conn., Aug. 15 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that the Company had paid interest due August 15, 2007 on its 7.75% Convertible Senior Notes due 2012 (the "Notes"). The aggregate principal amount of the Notes is $60 million.

The Company paid $2,260,416.67 in interest through the issuance of shares of its registered Common Stock. Approximately $2,259,888 was paid in 2,539,200 shares of Common Stock, based on today's closing bid price of $0.89, which is approximately equal to 42.32 of shares of Common Stock per each $1,000 principal amount of Notes. Cash interest was paid in lieu of fractional shares.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. A Phase II trial of Cloretazine(R) (VNP40101M) in small cell lung cancer is also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at '/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Anthropology professors blog raises public interest
4. Interest drives investment of instructional technology
5. High interest forces delay in food safety symposium
6. A Vote Against Free Trade is a Vote Against Wisconsins Long-Term Interests
7. SecurePipe appoints two senior execs
8. Third Wave announces two senior management appointments
9. Senior Wisconsin stem-cell researcher leaves for Connecticut
10. Sonic Foundry names new senior vice president
11. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... The World Molecular Imaging Society (WMIS) Board ... as Executive Director. Baird will assume leadership of ... WMIS vision is to encompass and promote preclinical and ... diseases in the developed and developing world. The ... by integrating the Academy of Molecular Imaging and the ...
(Date:5/17/2013)... Topricin Pain Relief and Healing ... listed among nationally recommended over-the-counter (OTC) health products ... "U.S. News" Health in collaboration with "Pharmacy Times." ... 1 Pharmacists Recommended designation” in the “Topical Analgesics” ... and is the only homeopathic formula to earn ...
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 The new ... Photonics21 at the association’s recent annual meeting drew ... EC Vice-President Neelie Kroes, who called the action “a ... and a stimulant to European innovation.” , The Board ... of the new Photonics PPP at its 29 April ...
Breaking Biology Technology:WMIS Appoints Lisa Baird as Next Executive Director 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3
... Additional donations to benefit St. Jude Children,s Research Hospital(R), ... by ... visiting promesayesperanza.org, MEMPHIS, Tenn., Feb. 14 More ... Esperanza (Promise and,Hope) radiothon held by Univision Radio, a division ...
... Feb. 14 CV Therapeutics,Inc. (Nasdaq: CVTX ... rule 4350, the Company issued new inducement stock ... hiring, primarily in,connection with its commercialization efforts in ... cover an aggregate 119,200 shares of,common stock and ...
... the,availability of MarketStats on public equities that are ... can view all of SectorWatch.biz MarketStats free of ... MarketStats, Today,s MarketStats on Healthcare and Biotechnology ... CVBT), Boston,Scientific Corp. (NYSE: BSX ), Medtronic ...
Cached Biology Technology:More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases 2More than $6 Million Raised During Two-Day Event to Support Research and Treatment for Childhood Cancer and Other Catastrophic Diseases 3CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA 2
(Date:5/17/2013)... white noise of the South, but the night belongs to ... hangs heavy from the humidity and the sounds of wildlife. ... of frogs, toads and salamanders, is the center of amphibian ... are the auditorium for their symphonic choruses, the scientists of ... ARMI, have front-row seats. , Amphibians, which rely ...
(Date:5/17/2013)... Sustainable Global Logistics Operations) is aiming to cut CO2 ... intermodal loading systems and the boosting of intelligent systems ... with experience in the logistics sector and in supply ... a duration of three and a half years. , ... components and ontologies shared by the users, objects and ...
(Date:5/16/2013)... Bethesda, MD FASEB MARC (Maximizing Access to ... recipients for The Endocrine Society (ENDO) 95th Annual ... 2013. These awards are meant to promote the ... groups into the mainstream of the basic science ... scientists at the ENDO 2013 Annual Meeting. , ...
Breaking Biology News(10 mins):Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... IRVINE, Calif., Feb. 17, 2012  ChromaDex Corporation (OTCBB: ... proprietary, science-based solutions and ingredients to the dietary ... and marketer of BluScience™ ( www.bluscience.com ... announced today that William F. Spengler has elected ...
... change we often hear about. But Mark Collard, a ... archaeology, will talk about how climate change impacts human ... American Association for the Advancement of Science (AAAS) conference ... Centre in downtown Vancouver., Collard will give a talk ...
... at SUNY Downstate Medical Center,s School of Public Health ... and environmental sources of exposure to mercury. The research, ... factors that may be associated with elevated mercury levels, ... study, published this month in the Journal of ...
Cached Biology News:ChromaDex® Announces Management Changes 2ChromaDex® Announces Management Changes 3AAAS-SFU research: Linking human evolution and climate change 2Study finds Caribbean-American women at higher risk for elevated mercury levels 2Study finds Caribbean-American women at higher risk for elevated mercury levels 3Study finds Caribbean-American women at higher risk for elevated mercury levels 4
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
SHEEP ANTI BOVINE LACTOPEROXIDASE...
... the ultimate in utility and flexibility press-to-seal ... the needs of the researcher. They are ... or as sheet material that can be ... isolators are autoclavable and non-cytotoxic and can ...
Request Info...
Biology Products: